Imai Norihiro, Takeda Kinichi, Utsunomiya Setsuo, Taga Masahiro, Kawata Noboru, Ikeda Takashi, Mizutani Yoshitaka, Hirose Ken, Ishikawa Tetsuya, Yoshida Shonen
Dept. of Gastroenterology, Nagoya Kyoritsu Hospital.
Gan To Kagaku Ryoho. 2010 Mar;37(3):527-9.
A 52-year-old woman with a chief complaint of epigastric distress was diagnosed as having pancreatic cancer with multiple liver metastases. After insertion of a metallic stent for biliary stenosis, combination therapy of gemcitabine (GEM) and adoptive immune cell therapy (AICT) was initiated. GEM 1,000 mg/m2 was administered on day 1, 8 and 15 every 4 weeks, while AICT using MUC1 peptide-pulsed dendritic cells (DC) and anti-CD3-activated T lymphocytes (CAT) was given biweekly. After 6 courses of GEM and 9 courses of DC-CAT, the patient was considered to have a complete response (CR) on CT and MRI examination. CR has still been maintained by the continuous administration of GEM and CAT. The combination therapy of GEM and AICT was suggested to be effective against advanced pancreatic cancer.
一名以中上腹不适为主诉的52岁女性被诊断为患有胰腺癌伴多发肝转移。在插入金属支架治疗胆道狭窄后,开始吉西他滨(GEM)与过继性免疫细胞治疗(AICT)的联合治疗。每4周在第1、8和15天给予GEM 1000 mg/m²,而使用MUC1肽脉冲树突状细胞(DC)和抗CD3激活T淋巴细胞(CAT)的AICT每两周进行一次。在6个疗程的GEM和9个疗程的DC-CAT治疗后,经CT和MRI检查,该患者被认为达到完全缓解(CR)。通过持续给予GEM和CAT,CR状态仍得以维持。提示GEM与AICT的联合治疗对晚期胰腺癌有效。